Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nintedanib Esylate

FDA-approved product (capsule, oral), marketed as Nintedanib Esylate, Ofev.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nintedanib Esylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic pulmonary fibrosis
  • Interstitial pneumonitis
  • Non-small cell lung carcinoma
  • Systemic scleroderma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nintedanib Esylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nintedanib Esylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia

    NCT04856111 · start 2021-03-17

    Registered record
    Registry ID
    NCT04856111
    Conditions
    Novel Coronavirus-induced Lung Fibrosis
    Interventions
    Pirfenidone; Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-03-17
    Completion
    2022-11-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNovel Coronavirus-induced Lung Fibrosis
    InterventionPirfenidone; Nintedanib
    PhasePhase 4
    Registry statusUnknown

  • Safety and Effectiveness of Nintedanib in Korean Patients

    NCT04525547 · start 2021-01-13

    Registered record
    Registry ID
    NCT04525547
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Nintedanib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2022-08-18
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionNintedanib
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes

    NCT04316780 · start 2019-04-15

    Registered record
    Registry ID
    NCT04316780
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Retrospective observational study- no intervention to occur.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-04-15
    Completion
    2020-03-01
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionRetrospective observational study- no intervention to occur.
    PhaseNot recorded
    Registry statusCompleted

  • Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    NCT03717012 · start 2018-11-15

    Registered record
    Registry ID
    NCT03717012
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Nintedanib; Pulmonary rehabilitation program
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-11-15
    Completion
    2020-06-10
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionNintedanib; Pulmonary rehabilitation program
    PhasePhase 4
    Registry statusTerminated

  • Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

    NCT03513484 · start 2018-11-14

    Registered record
    Registry ID
    NCT03513484
    Conditions
    Acute Myeloid Leukemia With t(9; 11)(p22.3; q23.3); MLLT3-KMT2A; Fibroblast Growth Factor Basic Form Measurement; FLT3 Internal Tandem Duplication; Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
    Interventions
    Azacitidine; Laboratory Biomarker Analysis; Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2018-11-14
    Completion
    2027-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With t(9; 11)(p22.3; q23.3); MLLT3-KMT2A +4 more
    InterventionAzacitidine; Laboratory Biomarker Analysis; Nintedanib
    PhasePhase 1
    Registry statusActive not recruiting

  • Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

    NCT02863055 · start 2018-02-04

    Registered record
    Registry ID
    NCT02863055
    Conditions
    Malignant Pleural Mesothelioma
    Interventions
    Nintedanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-04
    Completion
    2024-01-10
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Pleural Mesothelioma
    InterventionNintedanib; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

    NCT03287414 · start 2017-12-20

    Registered record
    Registry ID
    NCT03287414
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    VAY736; Placebo; Standard of Care (SoC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-12-20
    Completion
    2022-02-14
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionVAY736; Placebo; Standard of Care (SoC)
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

    NCT03363815 · start 2017-12-04

    Registered record
    Registry ID
    NCT03363815
    Conditions
    Heathy Volunteer
    Interventions
    CC-90001; Omeprazole; Midazolam; Warfarin; Vitamin K; Rosuvastatin; Metformin; Digoxin; Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-04
    Completion
    2018-07-29
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeathy Volunteer
    InterventionCC-90001; Omeprazole; Midazolam; Warfarin +5 more
    PhasePhase 1
    Registry statusCompleted

  • LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

    NCT03287947 · start 2017-11-10

    Registered record
    Registry ID
    NCT03287947
    Conditions
    Appendix Cancer
    Interventions
    nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-11-10
    Completion
    2019-10-27
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendix Cancer
    Interventionnintedanib
    PhasePhase 2
    Registry statusTerminated

  • Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

    NCT03281200 · start 2017-10-24

    Registered record
    Registry ID
    NCT03281200
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    L - Antineoplastic and immunomodulating agents; L01 - Antineoplastic agents; L01X - Other antineoplastic agents; L01XE - Protein kinase inhibitors; L01XE31 - Nintedanib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-10-24
    Completion
    2018-06-07
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionL - Antineoplastic and immunomodulating agents; L01 - Antineoplastic agents; L01X - Other antineoplastic agents; L01XE - Protein kinase inhibitors +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

    NCT03242759 · start 2017-08-17

    Registered record
    Registry ID
    NCT03242759
    Conditions
    Pulmonary Fibrosis
    Interventions
    nintedanib; pirfenidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-08-17
    Completion
    2020-02-18
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Fibrosis
    Interventionnintedanib; pirfenidone
    PhaseNot recorded
    Registry statusCompleted

  • Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

    NCT03047031 · start 2017-04-05

    Registered record
    Registry ID
    NCT03047031
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Nintedanib; Pirfenidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-04-05
    Completion
    2022-07-21
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionNintedanib; Pirfenidone
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

    NCT02999178 · start 2017-01-17

    Registered record
    Registry ID
    NCT02999178
    Conditions
    Lung Diseases, Interstitial
    Interventions
    Nintedanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01-17
    Completion
    2019-08-12
    Enrolment
    663

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Diseases, Interstitial
    InterventionNintedanib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

    NCT02802345 · start 2016-06-30

    Registered record
    Registry ID
    NCT02802345
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Nintedanib; Placebo; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-06-30
    Completion
    2018-04-13
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionNintedanib; Placebo; Sildenafil
    PhasePhase 3
    Registry statusCompleted

  • Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

    NCT02568449 · start 2016-03-15

    Registered record
    Registry ID
    NCT02568449
    Conditions
    Recurrent Pleural Malignant Mesothelioma; Stage IV Pleural Mesothelioma
    Interventions
    Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-03-15
    Completion
    2018-06-26
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Pleural Malignant Mesothelioma; Stage IV Pleural Mesothelioma
    InterventionNintedanib
    PhasePhase 2
    Registry statusCompleted